Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

Dupixent (dupilumab) is tipped to be the market ... strong performance in clinical trials improving atopic dermatitis (AD) in moderate-to-severe patients, where it is the first systemic drug ...

If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

The cost of Dupixent can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Dupixent. Specifically ...

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...